Aquatic Capital Management’s Adicet Bio ACET Stock Holding History

Aquatic Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-256	Closed	-$37K	–	1204
2022 Q4	$37K	Buy	+256	New	+$63.9K	﹤0.01%	1064

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Aquatic Capital Management's ACET Position: Q1 2023 in Review

Aquatic Capital Management sold out of Adicet Bio (ACET) in Q1 2023, closing a stake of 256 shares — an estimated $37K sold.

Aquatic Capital Management first reported a position in ACET in Q4 2022 and held it in 1 quarter. The position peaked at $37K in Q4 2022. 107 funds tracked by Wall St. Rank hold ACET as of Q1 2023.

Aquatic Capital Management reported no remaining Adicet Bio position as of Q1 2023 after selling out during the quarter.
Aquatic Capital Management sold 256 Adicet Bio shares in Q1 2023, an estimated $37K.
Aquatic Capital Management first reported a position in Adicet Bio in Q4 2022 and held it in 1 quarter.
Aquatic Capital Management's Adicet Bio position peaked at $37K in Q4 2022.
107 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2023.

Based on Aquatic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.